US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
CA2462144C
(en)
*
|
2001-09-28 |
2016-09-20 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Micro-rna molecules
|
WO2005013901A2
(en)
*
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US20050261217A1
(en)
|
2004-05-18 |
2005-11-24 |
Isis Pharmaceuticals Inc. |
Modulation of pumilio 1 expression
|
US7642348B2
(en)
|
2004-10-04 |
2010-01-05 |
Rosetta Genomics Ltd |
Prostate cancer-related nucleic acids
|
US20070259349A1
(en)
|
2006-05-04 |
2007-11-08 |
Itzhak Bentwich |
Bladder cancer-related nucleic acids
|
US7825229B2
(en)
|
2005-03-25 |
2010-11-02 |
Rosetta Genomics Ltd. |
Lung cancer-related nucleic acids
|
US7592441B2
(en)
|
2004-10-04 |
2009-09-22 |
Rosetta Genomics Ltd |
Liver cancer-related nucleic acids
|
EP2281888B1
(de)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen, die miRNA und miRNA-inhibitorischen Molekülen verbunden sind
|
AU2006242154B2
(en)
|
2005-05-02 |
2011-11-03 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
WO2006133022A2
(en)
|
2005-06-03 |
2006-12-14 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
AU2006254732A1
(en)
|
2005-06-03 |
2006-12-07 |
Southern Adelaide Health Service-Flinders Medical Centre |
Targeting cells with altered microrna expression
|
CA2617581A1
(en)
|
2005-08-01 |
2007-02-08 |
The Ohio State University Research Foundation |
Microrna-based methods for the diagnosis of breast cancer
|
ES2523989T3
(es)
|
2005-09-12 |
2014-12-03 |
The Ohio State University Research Foundation |
Composiciones para la terapia de cánceres asociados con BCL2
|
EP1968622B1
(de)
|
2006-01-05 |
2014-08-27 |
The Ohio State University Research Foundation |
Mikro-rna-expressions-anomalien in pankreas- und azinus-tumoren
|
CN102943108B
(zh)
|
2006-01-05 |
2014-05-21 |
俄亥俄州立大学研究基金会 |
用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
|
ES2461189T3
(es)
|
2006-01-05 |
2014-05-19 |
The Ohio State University Research Foundation |
Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
|
EP2522750A1
(de)
|
2006-03-02 |
2012-11-14 |
The Ohio State University |
Mikro-RNA-Expressionsprofil im Zusammenhang mit Bauchspeicheldrüsenkrebs
|
EP2369012A1
(de)
|
2006-03-20 |
2011-09-28 |
The Ohio State University Research Foundation |
Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese
|
CA3042781C
(en)
|
2006-04-03 |
2021-10-19 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
EA201100813A1
(ru)
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
US20080076674A1
(en)
|
2006-07-06 |
2008-03-27 |
Thomas Litman |
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
|
ES2425387T3
(es)
|
2006-07-13 |
2013-10-15 |
The Ohio State University Research Foundation |
Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
|
WO2008014008A2
(en)
|
2006-07-28 |
2008-01-31 |
The Johns Hopkins University |
Compositions and methods for modulating angiogenesis
|
WO2008036718A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-143 regulated genes and pathways as targets for therapeutic intervention
|
AU2007299804A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
MiR-200 regulated genes and pathways as targets for therapeutic intervention
|
EP2090665A2
(de)
|
2006-10-20 |
2009-08-19 |
Exiqon A/S |
Neue humane MikroRNAs im Zusammenhang mit Krebs
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
US20090137504A1
(en)
|
2006-12-21 |
2009-05-28 |
Soren Morgenthaler Echwald |
Microrna target site blocking oligos and uses thereof
|
EP3536788A1
(de)
|
2006-12-21 |
2019-09-11 |
QIAGEN GmbH |
Mikro-rna-zielortblockierende oligos und verwendungen davon
|
EP2124967A4
(de)
|
2007-01-26 |
2011-01-05 |
Rosetta Genomics Ltd |
Zusammensetzungen und verfahren zur behandlung von hämatopoietischen malignomen
|
US20100310583A1
(en)
|
2007-01-31 |
2010-12-09 |
Immune Disease Institute |
Let-7 microrna and mimetics thereof as therapeutics for cancer
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
WO2008137862A2
(en)
|
2007-05-03 |
2008-11-13 |
Rosetta Inpharmatics Llc |
Methods of using mir34 as a biomarker for tp53 functional status
|
CA2693031A1
(en)
*
|
2007-07-18 |
2009-01-22 |
The Regents Of The University Colorado |
Differential expression of micrornas in nonfailing versus failing human hearts
|
CN101939446B
(zh)
|
2007-09-06 |
2015-02-11 |
俄亥俄州立大学研究基金会 |
人类卵巢癌中的微小rna特征
|
WO2009036332A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
ES2575868T3
(es)
|
2007-09-14 |
2016-07-01 |
The Ohio State University Research Foundation |
Expresión de miARN en microvesículas de sangre periférica humana y sus usos
|
US20090136957A1
(en)
|
2007-09-15 |
2009-05-28 |
Irena Ivanovska |
Methods and compositions for regulating cell cycle progression via the miR-106B family
|
AU2008310704B2
(en)
|
2007-10-11 |
2014-03-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
|
WO2009058907A2
(en)
|
2007-10-29 |
2009-05-07 |
Isis Pharmaceuticals, Inc. |
Targeting micrornas for the treatment of liver cancer
|
WO2009075787A1
(en)
|
2007-12-05 |
2009-06-18 |
The Johns Hopkins University |
Compositions and methods of treating neoplasia
|
EP3112477A1
(de)
|
2008-02-28 |
2017-01-04 |
The Ohio State University Research Foundation |
Verfahren und zusammensetzungen auf mikro-rna-basis zur diagnose, prognose und behandlung von mit prostatakrebs verwandten erkrankungen
|
WO2009120712A2
(en)
|
2008-03-24 |
2009-10-01 |
New York University |
Compositions and methods for diagnosing and treating melanoma
|
US20090253780A1
(en)
|
2008-03-26 |
2009-10-08 |
Fumitaka Takeshita |
COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
|
US20100113284A1
(en)
|
2008-04-04 |
2010-05-06 |
Alexander Aristarkhov |
Small interfering rna (sirna) target site blocking oligos and uses thereof
|
US20090258928A1
(en)
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc. |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
US20110166200A1
(en)
|
2008-04-24 |
2011-07-07 |
Zhan Zhang |
Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
|
EP2296669B1
(de)
|
2008-05-30 |
2012-03-21 |
Yale University |
Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
|
EP2294218A2
(de)
|
2008-06-02 |
2011-03-16 |
New York University |
Zusammensetzungen und verfahren zur diagnose, prognose und behandlung von mesotheliom
|
EP2300017A4
(de)
*
|
2008-06-05 |
2012-12-12 |
Univ New York State Res Found |
Mirnas als therapeutische targets bei krebs
|
WO2009153774A2
(en)
|
2008-06-17 |
2009-12-23 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis of ovarian cancer
|
WO2010005850A1
(en)
|
2008-07-08 |
2010-01-14 |
The J. David Gladstone Institutes |
Methods and compositions for modulating angiogenesis
|
US20110118337A1
(en)
|
2008-07-10 |
2011-05-19 |
Merck Sharp & Dohme Corp. |
Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
|
WO2010023658A2
(en)
|
2008-08-28 |
2010-03-04 |
Rosetta Genomics Ltd. |
Compositions and methods for the treatment of glioblastoma
|
CN102239260B
(zh)
|
2008-10-03 |
2017-04-12 |
库尔纳公司 |
通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
|
US8729041B2
(en)
|
2008-12-03 |
2014-05-20 |
The Johns Hopkins University |
Compositions and methods for treating hepatic neoplasia
|
US8927511B2
(en)
|
2008-12-04 |
2015-01-06 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
|
MX366774B
(es)
|
2008-12-04 |
2019-07-24 |
Curna Inc |
Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
|
CA2745811C
(en)
|
2008-12-04 |
2021-07-13 |
Joseph Collard |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
JP2012510813A
(ja)
|
2008-12-05 |
2012-05-17 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション |
卵巣癌の診断および治療のためのマイクロrnaに基づく方法および組成物
|
US20100311815A1
(en)
|
2009-02-23 |
2010-12-09 |
The Regents Of The University Of Michigan |
Mir-101 cancer markers
|
EP2401406A4
(de)
*
|
2009-02-25 |
2012-09-19 |
Cepheid |
Verfahren für den nachweis von lungenkrebs
|
EP2963116B1
(de)
|
2009-03-04 |
2020-11-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
|
US8735568B2
(en)
|
2009-03-09 |
2014-05-27 |
The J. David Gladstone Institutes |
Methods of modulating smooth muscle cell proliferation and differentiation
|
WO2010108192A1
(en)
*
|
2009-03-20 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Mirnas as therapeutic targets in cancer
|
WO2010115050A2
(en)
*
|
2009-04-01 |
2010-10-07 |
The Regents Of The University Of California |
Embryonic stem cell specific micrornas promote induced pluripotency
|
DK2425016T3
(en)
*
|
2009-04-29 |
2015-06-29 |
Amc Amsterdam |
MEANS AND METHODS TO REMEDY THE, PREVENT AND / OR diagnose heart failure or EN risk of cardiac failure
|
CN102639151B
(zh)
|
2009-05-01 |
2017-03-22 |
库尔纳公司 |
通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白(hbf/hbg)相关疾病
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
KR100998365B1
(ko)
|
2009-06-29 |
2010-12-06 |
압타바이오 주식회사 |
치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
|
WO2011014980A1
(en)
|
2009-08-07 |
2011-02-10 |
Capitalbio Corporation |
Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival
|
WO2011021177A2
(en)
|
2009-08-19 |
2011-02-24 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis and treatment of prostate cancer
|
WO2011024157A1
(en)
|
2009-08-23 |
2011-03-03 |
Rosetta Genomics Ltd. |
Nucleic acid sequences related to cancer
|
US9157080B2
(en)
|
2009-09-09 |
2015-10-13 |
New York University |
Compositions and methods for treatment, diagnosis and prognosis of mesothelioma
|
US8648017B2
(en)
*
|
2009-11-04 |
2014-02-11 |
Diamir, Llc |
Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
|
JP6025567B2
(ja)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療
|
RU2611186C2
(ru)
|
2009-12-29 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
US8846631B2
(en)
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
EP2539452B1
(de)
|
2010-02-22 |
2016-07-27 |
CuRNA, Inc. |
Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
|
EP3214174B1
(de)
*
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
Mirna-molekül, das über seine quelle definiert ist, und seine diagnostischen und therapeutischen verwendungen bei mit emt assoziierten krankheiten
|
US20130059015A1
(en)
|
2010-03-11 |
2013-03-07 |
H. Lee Moffitt Cancer Center & Research Institute |
Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
|
US9526693B2
(en)
|
2010-03-16 |
2016-12-27 |
Sanford-Burnham Medical Research Inslilute |
Delivery of agents using interfering nanoparticles
|
EP2556160A4
(de)
|
2010-04-09 |
2013-08-21 |
Curna Inc |
Behandlung von erkrankungen im zusammenhang mit dem fibroblastenwachstumsfaktor 21 (fgf21) mittels hemmung des natürlichen antisense-transkripts gegen fgf21
|
WO2011128886A1
(en)
|
2010-04-12 |
2011-10-20 |
Ramot At Tel Aviv University Ltd. |
A micro-rna for cancer diagnosis, prognosis and therapy
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
TW201201819A
(en)
|
2010-05-19 |
2012-01-16 |
Opko Curna Llc |
Treatment of BCL2-like 11 (BCL2L11) related diseases by inhibition of natural antisense transcript to BCL2L11
|
EP3299464B1
(de)
|
2010-05-26 |
2019-10-02 |
CuRNA, Inc. |
Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
|
WO2011157294A1
(en)
|
2010-06-16 |
2011-12-22 |
Universita' Degli Studi Di Padova |
Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
|
TW201209163A
(en)
|
2010-07-12 |
2012-03-01 |
Opko Curna Llc |
Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
|
US9333218B2
(en)
*
|
2010-07-15 |
2016-05-10 |
Emory University |
MicroRNA compositions and methods related thereto
|
US20130123138A1
(en)
|
2010-07-25 |
2013-05-16 |
New York University |
Compositions and methods for prognosis of mesothelioma
|
US8980549B2
(en)
|
2010-08-01 |
2015-03-17 |
Ramot At Tel Aviv University Ltd. |
MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma
|
CA2813901C
(en)
|
2010-10-06 |
2019-11-12 |
Curna, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
KR101343616B1
(ko)
|
2010-10-08 |
2013-12-20 |
연세대학교 산학협력단 |
췌장암 치료용 약제학적 조성물 및 췌장암 치료제 스크리닝 방법
|
WO2012065143A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
JP2014502606A
(ja)
|
2010-12-15 |
2014-02-03 |
メディミューン,エルエルシー |
黒色腫の処置
|
AU2011352036A1
(en)
*
|
2010-12-31 |
2013-07-18 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory RNA molecules
|
US8883757B2
(en)
|
2011-01-03 |
2014-11-11 |
Rosetta Genomics Ltd. |
Compositions and methods for treatment of ovarian cancer
|
EP2474617A1
(de)
*
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
CN103459598B
(zh)
*
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
US9132152B2
(en)
|
2011-02-10 |
2015-09-15 |
The Regents Of The University Of California |
Compositions and methods for generating induced pluripotent stem cells
|
CA2830301A1
(en)
|
2011-03-18 |
2012-09-27 |
Baylor Research Institute |
Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
|
US8987224B2
(en)
*
|
2011-08-05 |
2015-03-24 |
Baylor College Of Medicine |
MicroRNA-198 as a tumor suppressor in pancreatic cancer
|
WO2013056216A1
(en)
*
|
2011-10-14 |
2013-04-18 |
New York University |
Micrornas and methods of using same
|
US9745578B2
(en)
|
2011-11-30 |
2017-08-29 |
Cedars-Sinai Medical Center |
Targeting microRNA miR-409-3P to treat prostate cancer
|
JP2015504847A
(ja)
|
2011-11-30 |
2015-02-16 |
シーダーズ−サイナイ メディカル センター |
前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロrnamir−409−5p、mir−379、およびmir−154*の標的化
|
US20140363469A1
(en)
*
|
2012-01-19 |
2014-12-11 |
Alnylam Pharmaceuticals, Inc. |
Viral attenuation and vaccine production
|
JP2015511494A
(ja)
|
2012-03-15 |
2015-04-20 |
キュアナ,インク. |
脳由来神経栄養因子(bdnf)に対する天然アンチセンス転写物の阻害によるbdnf関連の疾患の処置
|
EP2838541A1
(de)
*
|
2012-04-20 |
2015-02-25 |
Agency For Science, Technology And Research |
Rnai-basierte therapien für kardiomyopathien, muskeldystrophien und laminopathien
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
AP2014008100A0
(en)
|
2012-05-16 |
2014-12-31 |
Gen Hospital Corp |
Compositions and methods for modulating hemoglobingene family expression
|
EP3511416A1
(de)
|
2012-05-16 |
2019-07-17 |
Translate Bio MA, Inc. |
Zusammensetzungen und verfahren zur modulation von genexpression
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
EP2850187A4
(de)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
Zusammensetzungen und verfahren zur pten-expressions-modulierung
|
CN104602714A
(zh)
|
2012-05-16 |
2015-05-06 |
Rana医疗有限公司 |
用于调节bdnf表达的组合物和方法
|
SG11201407486PA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating utrn expression
|
EP2849801A4
(de)
|
2012-05-16 |
2016-05-25 |
Rana Therapeutics Inc |
Zusammensetzungen und verfahren zur modulierung der apoa1- und abca1-expression
|
US9758785B2
(en)
|
2012-07-12 |
2017-09-12 |
Baylor College Of Medicine |
miR-520 microRNAs sensitize cancers to platinum-based therapy
|
US9096853B2
(en)
*
|
2012-09-24 |
2015-08-04 |
U.S. Department Of Veterans Affairs |
Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
|
CN109793897B
(zh)
|
2012-10-31 |
2022-02-01 |
洛克菲勒大学 |
结肠癌的治疗和诊断
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
WO2014100252A1
(en)
*
|
2012-12-18 |
2014-06-26 |
University Of Washington Through Its Center For Commercialization |
Methods and compositions to modulate rna processing
|
WO2014186462A1
(en)
*
|
2013-05-15 |
2014-11-20 |
The Research Foundation For The State University Of New York |
Microrna-129 as a biomarker for colorectal cancer
|
AU2014274730A1
(en)
|
2013-06-07 |
2016-01-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating FOXP3 expression
|
US20150151004A1
(en)
*
|
2013-06-14 |
2015-06-04 |
The University Of Kansas |
Methods and compositions of modulating tumor initiating cells and the use thereof
|
WO2015066034A1
(en)
*
|
2013-10-28 |
2015-05-07 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for modulating neuronal excitability and motor behavior
|
WO2015095862A2
(en)
|
2013-12-20 |
2015-06-25 |
The Feinstein Institute For Medical Research |
Microrna biomarkers for ovarian cancer
|
EP3105327A4
(de)
|
2014-02-12 |
2017-10-18 |
Thomas Jefferson University |
Zusammensetzungen und verfahren zur verwendung von mikrorna-inhibitoren
|
KR101596166B1
(ko)
|
2014-10-07 |
2016-02-19 |
가톨릭대학교 산학협력단 |
유방암 진단 및 치료를 위한 마이크로 rna의 용도
|
EP3271460A4
(de)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
Rna-interaktom des polycomb-repressiven komplexes 1 (prc1)
|
ES2965461T3
(es)
|
2015-08-03 |
2024-04-15 |
Biokine Therapeutics Ltd |
Inhibidor de CXCR4 para el tratamiento del cáncer
|
US10053696B2
(en)
|
2016-01-21 |
2018-08-21 |
University Of South Carolina |
MiRNA-489 in treatment of breast cancer
|
US11236337B2
(en)
|
2016-11-01 |
2022-02-01 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
AU2017353907B2
(en)
*
|
2016-11-01 |
2023-11-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
US10443055B2
(en)
|
2016-12-22 |
2019-10-15 |
Beth Israel Deaconess Medical Center |
Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
EP3571212B1
(de)
|
2017-01-23 |
2024-03-06 |
Trustees of Boston University |
Verfahren im zusammenhang mit lungenkrebs
|
KR101953300B1
(ko)
|
2018-06-22 |
2019-02-28 |
의료법인 성광의료재단 |
탁산계 항암제 내성 암의 진단 및 치료를 위한 조성물, 키트 및 방법
|
US20220298516A1
(en)
|
2018-09-20 |
2022-09-22 |
Modernatx, Inc. |
Compositions and methods for delivery of nucleic acids
|
US20220096517A1
(en)
|
2018-11-13 |
2022-03-31 |
Regulus Therapeutics Inc. |
MicroRNA Compounds and Methods for Modulating MIR-10B Activity
|
WO2020154207A1
(en)
|
2019-01-22 |
2020-07-30 |
Research Institute At Nationwide Children's Hospital |
A novel method for monitoring and treating oral cancer
|
KR20210139237A
(ko)
|
2019-03-14 |
2021-11-22 |
더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 |
변형된 마이크로rna 및 암 치료에 있어서의 이의 용도
|
WO2021097437A1
(en)
|
2019-11-14 |
2021-05-20 |
The Board Of Regents Of The University Of Oklahoma |
Oligonucleotide interference treatments of prostate cancer
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|